ALBO:NSD-Albireo Pharma, Inc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 16.56

Change

-2.05 (-11.02)%

Market Cap

USD 0.23B

Volume

0.07M

Average Target Price

USD 39.00 (+135.51%)
Average Analyst Rating

Verdict

Fundamental Analysis

Verdict

About

Albireo Pharma, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and gastrointestinal (GI) disorders in the United States. Its lead product candidate is A4250, an orally administered ileal sodium dependent bile acid transporter (IBAT) inhibitor that is in phase III clinical trial for treating progressive familial intrahepatic cholestasis and phase II clinical trial for treating biliary atresia, alagille syndrome, and other cholestatic liver diseases. The company is also developing Elobixibat, an orally administered IBAT inhibitor for the treatment of chronic constipation and other functional diseases, and nonalcoholic steatohepatitis; and A3384 for the treatment of bile acid malabsorption. It has a license agreement with EA Pharma for the development and commercialization of elobixibat. Albireo Pharma, Inc. is headquartered in Boston, Massachusetts.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-03-27 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
VRTX Vertex Pharmaceuticals Incorpo..

-7.25 (-3.23%)

USD57.85B 49.47 37.66
REGN Regeneron Pharmaceuticals, Inc

-2.78 (-0.61%)

USD49.46B 24.35 19.19
ALXN Alexion Pharmaceuticals, Inc

-2.13 (-2.47%)

USD19.07B 8.05 7.52
SGEN Seattle Genetics, Inc

-6.87 (-5.92%)

USD17.09B N/A -97.94
INCY Incyte Corporation

-4.09 (-5.60%)

USD14.95B 33.64 28.94
BMRN BioMarin Pharmaceutical Inc

-3.13 (-3.79%)

USD13.14B N/A 29,715.80
GMAB Genmab A/S

+0.09 (+0.45%)

USD12.83B N/A N/A
GLPG Galapagos NV

-5.35 (-2.85%)

USD11.88B 72.40 N/A
ALNY Alnylam Pharmaceuticals, Inc

-3.01 (-2.81%)

USD11.15B N/A -11.34
BGNE BeiGene, Ltd

-0.77 (-0.61%)

USD10.58B N/A -9.67

ETFs Containing ALBO

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -34.85% 38% F 37% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -34.85% 38% F 36% F
Trailing 12 Months  
Capital Gain -47.96% 37% F 27% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -47.96% 37% F 26% F
Trailing 5 Years  
Capital Gain -53.22% 52% F 31% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -53.22% 51% F 28% F
Average Annual (5 Year Horizon)  
Capital Gain 27.25% 77% C+ 84% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 27.25% 77% C+ 83% B
Risk Return Profile  
Volatility (Standard Deviation) 64.78% 27% F 13% F
Risk Adjusted Return 42.07% 77% C+ 53% F
Market Capitalization 0.23B 55% F 53% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A N/A N/A
Price/Book Ratio 2.14 57% F 38% F
Price / Cash Flow Ratio -4.41 58% F 79% C+
EV/EBITDA -1.74 51% F 73% C
Management Effectiveness  
Return on Equity -58.13% 58% F 21% F
Return on Invested Capital -56.64% 49% F 17% F
Return on Assets -21.79% 69% D+ 20% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 3.51 53% F 43% F
Short Percent 4.87% 61% D- 44% F
Beta 1.33 57% F 31% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector